Unique risk factors for bacteraemia in allogeneic bone marrow transplant recipients before and after engraftment.
A study of the risk factors associated with bacteraemia in 191 allogeneic bone marrow transplant (BMT) recipients (1991-1996) was performed. In contrast to risk factors commonly cited for cancer chemotherapy, mucositis, degree of conditioning toxicity of the gut and lungs, duration of neutropenia, and severity of neutropenia and monocytopenia were not associated with bacteraemia in the pre-engraftment period, during which the only significant risk factor was late stage underlying disease (P < 0.05). After engraftment, Hickman catheter infection, and severe acute and chronic graft-versus-host disease (GVHD) were found to be independently associated with bacteraemia by multivariate analysis (P < 0.001, <0.05 and <0.05, respectively). This might be explained by intense antimicrobial prophylaxis, early empirical treatment, and non-routine use of haemopoietic growth factors. No significant difference in mortality was detected between bacteraemic and non-bacteraemic patients in both periods. Allogeneic BMT recipients are therefore a group of patients distinct from other cancer patients receiving chemotherapy at risk of developing bacteraemia. The study findings prompt consideration of a management protocol incorporating early and routine use of haemopoietic growth factors before engraftment in high-risk patients with late stage underlying malignancies, routine antimicrobial prophylaxis for acute GVHD with intense immunosuppression, and intravenous immunoglobulin therapy for chronic GVHD. Further cost-benefit analyses are warranted.
Yuen
K Y
KY
Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
Woo
P C
PC
Hui
C H
CH
Luk
W K
WK
Chen
F E
FE
Lie
A K
AK
Liang
R
R
D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage; D016470:Bacteremia / Q000209:etiology* / Q000517:prevention & control; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002405:Catheterization, Central Venous / Q000009:adverse effects; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D013997:Time Factors; D014184:Transplantation, Homologous
D000890:Anti-Infective Agents; D016298:Hematopoietic Cell Growth Factors